RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis - MultiVu
3/16/2022 12:00:00 AM3 years 1 month ago
by MultiVu - PR Newswire
by MultiVu - PR Newswire
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., March 16, 2022 AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderatel… [+27039 chars]
full article...